This is a summary. To read the whole story subscribe to BostonGlobe.com
Combine an emerging company at the vanguard of personalized cancer treatment with a white-hot market for biotech IPOs, and you have a recipe for the next rocket-propelled stock.
That’s the hope, at least, for Foundation Medicine of Cambridge, a supplier of genomic testing for cancer patients that filed plans Tuesday with federal regulators to raise $86.25 million by giong public.
The biotechnology company with an all-star list of advisers and investors could become the sixth from Massachusetts to launch an initial public offering this year — and the third backed by Boston’s Third Rock Ventures — adding to what is already the nation’s biggest coming-out class of public companies since 2007.